Učitavanje...

Evolution of Therapies for Chronic Myelogenous Leukemia

The clinical outcome for patients with chronic myeloid leukemia (CML) has changed dramatically in the past 15 years. This has been due to the development of tyrosine kinase inhibitors (TKI), compounds which inhibit the activity of the oncogenic BCR-ABL1 protein. Imatinib was the first TKI developed...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Santos, Fabio P S, Kantarjian, Hagop, Quintás-Cardama, Alfonso, Cortes, Jorge
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3243359/
https://ncbi.nlm.nih.gov/pubmed/22157290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0b013e31823dec8d
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!